Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18228248 | 0.98 | KDM4E (0.48) | KDM4EHRH4DPP4DPP8DPP9 | |
| SCHEMBL23498149 | 0.90 | KMT2A (0.48) | HRH4ROCK2ROCK1CDC42BPB | |
| SCHEMBL15029579 | 0.90 | KMT2A (0.48) | HRH4ROCK2ROCK1CDC42BPB | |
| SCHEMBL1346067 | 0.89 | KDM4E (0.55) | KDM4EGPR119HRH3RXFP1 | |
| Hydrochloric Acid SCHEMBL20141683 | 0.88 | KDM4E (0.54) | KDM4EGPR119HRH3RXFP1 | |
| SCHEMBL20064219 | 0.85 | GRM1 (0.44) | KDM4EHRH4DPP4DPP8DPP9 | |
| SCHEMBL1267664 | 0.79 | KDM4E (0.49) | KDM4EDPP4DPP8DPP9DPP7 | |
| SCHEMBL24928451 | 0.79 | KDM4E (0.52) | KDM4EDPP4DPP8DPP9DPP7 | |
| SCHEMBL13035375 | 0.79 | KDM4E (0.52) | KDM4EGPR119RXFP1 | |
| SCHEMBL30718898 | 0.79 | KDM4E (0.52) | KDM4EDPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | KDM4E 1664/4885HRH4 854/4885DPP4 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.